TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06240455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WP1302
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WP1302
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WP1302
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Study: NCT05032235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Normal Renal Function:A single oral dose of Fluzoparib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.
Study: NCT06240455

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WP1302 placebo
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: methimazole
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Study: NCT05032235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
Study: NCT04155099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBX7455
Description: RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBX7455
Description: RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with cellulose filler
Study: NCT05908448

Intervention type: DEVICE
Intervention: 13 CGM (continuous glucose monitor)
Description: The I3 CGM consists of three main components: a Sensor Pack (Applicator-Sensor assembly), a Transmitter Pack (with Bluetooth Low Energy (BLE)) and a mobile application (I3 CGM App). The user can view their glucose data on the I3 CGM App running on a compatible mobile device.
Study: NCT06240455

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: methimazole
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: methimazole
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Study: NCT06240455

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: methimazole
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Study: NCT06441305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SWITCH intervention package
Description: * Addition of digital monitoring \& supervision by CHA~* Digitized registration of households by CHPs every 6 months~* Digital reminders to CHP to conduct home visit if a child has never been visited in 3 mo.~* Digital reminder for timely training to family MUAC of all family members through home visit by CHP when child turns 6 months of age.~* Platform for 2-ways messaging: biweekly SMS reminders to caregivers through the CHP's app; feedback by caregiver~* Community level screening based on weight and weight-for-age (WAZ) led by CHP every other month (aligned with Community Action Days),~* Digital calculation of WAZ.~* CHP and Growth Monitoring and Promotion refer to health facility if WAZ\<-3 to check on WHZ eligibility~* At the end of every wasting treatment consultation, compilation of the list of defaulters and non-respondents, for immediate transmission by CHA to relevant CHP through digital task of an instruction for immediate follow-up.
Study: NCT06635642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dichotic Interaural Intensity Difference (DIID) Training
Description: A total of five trials will be presented in a sequence and there will be 10 sequences per training session. Each of the 25 consonant-vowel-consonant words or digits 1 through 10 (excluding 7) will be presented to each ear during the session. The pairs will be randomized every time, and a word will never be paired with itself. After a sequence is completed, the difficulty of the task will be adjusted, in real time, based on performance on the prior task. If the child scored 4 or 5 of 5 correct in the poorer ear, then the IID will be decreased by 2 dB making the task more difficult. If the child scores 0, 1, or 2 of 5 correct, then the IID will be increased by 2 dB making the task easier. Last, if the child scores 3 of 5 correct, then the IID will remain unchanged for the next sequence.
Study: NCT06510231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training (IMT) targets the inspiratory muscles and is used to improve inspiratory muscle strength.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training (IMT) targets the inspiratory muscles and is used to improve inspiratory muscle strength.
Study: NCT04539873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL GROUP
Description: In this case, the centers where the patients are enrolled will adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases)
Study: NCT05873452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kaitoh Atherectomy System
Description: The Kaitoh Atherectomy System is a handheld device which initiates mechanical rotation of the blade to debulk atherosclerotic lesions.
Study: NCT05216835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabestomig (AZD7789)
Description: Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabestomig (AZD7789)
Description: Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabestomig (AZD7789)
Description: Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.
Study: NCT05924100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept Injection [Reblozyl]
Description: Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg).~All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit.
Study: NCT05338853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gongs mobilization
Description: to deal adhesive capsulitis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular mobilization
Description: scapular mobilization
Study: NCT05740215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F520
Description: F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules
Study: NCT06458751

Intervention type: OTHER
Group type: OTHER
Intervention: electrophysiological study
Description: Antidromic sensory nerve conduction studies of median and ulnar nerves will be performed on both hands of 30 healthy subjects with no history of previous neuromuscular disease and no abnormalities on neurological examination., by using surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.

Intervention type: DEVICE
Group type: OTHER
Intervention: electromyograph
Description: surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
Study: NCT05188417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban 0.05 MG/ML
Description: intravenous injection of the drug according to different body weights and arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban 0.05 MG/ML
Description: intravenous injection of the drug according to different body weights and arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: intravenous injection of the drug according to different body weights and arms
Study: NCT04973800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg
Description: Simvastatin 20mg ON PO for 28-30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sucrose placebo ON PO for 28-30 days
Study: NCT06162507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection
Study: NCT04768062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viltolarsen
Description: Received during weekly intravenous infusions
Study: NCT06476899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orelabrutinib
Description: orelabrutinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCR/BR
Description: FCR/BR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTK inhibitor
Description: BTK inhibitor choose by physican
Study: NCT06039774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α-Mangostin Hydrogel Film With Chitosan Alginate Base
Description: Patients will apply α-Mangostin Hydrogel Film With Chitosan Alginate Base once a day for 7 days
Study: NCT05225584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-333
Description: KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-333
Description: KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-333
Description: KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-333
Description: KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-333
Description: KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-333
Description: KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.
Study: NCT06392607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euclid orthokeratology (standard coating)
Description: Lens with the current coating
Study: NCT06039774

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05225584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-333
Description: KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-333
Description: KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.
Study: NCT01171079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: application of oxidized regenerated cellulose
Study: NCT06392607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euclid orthokeratology (enhanced coating)
Description: Lens with the enhanced coating
Study: NCT06351020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: The subjects will receive Apatinib orally,qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle
Study: NCT04514133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participating in Action Civics program
Description: Students in school classrooms participating in Action Civics program
Study: NCT04655235

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes
Study: NCT06080958

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT
Description: the NPWT dressing applied to fasciocutaneous flap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT
Description: the NPWT dressing applied to fasciocutaneous flap
Study: NCT06383806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Description: The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. During the sessions, participants will learn techniques for managing and changing nightmares.
Study: NCT05780697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of Drainage of septic hip arthritis
Description: Surgery for septic hip arthritis by anterior or lateral approach and inspection of femoral head
Study: NCT06080958

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional dressing
Description: Conventional dressing ( topical care ) applied to fasciocutaneous flap
Study: NCT04259762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast, Colorectal, and Cervical Cancer Screening Interventions
Description: Adult men and women will receive age- and gender-specific interventions. Women age 50-75 years will receive the interventions for breast, colorectal, and cervical cancers screening. Men age 50-75 years will receive the intervention for colorectal cancer screening. Women age 21-49 years will receive the intervention for cervical cancer screening. The 4-week interventions, delivered once a week, will consist of educational sessions that discuss cancer-specific information (i.e., breast, colorectal, and cervical cancer): breast (colorectal, cervical) cancer myths and facts, risk factors and symptoms, screening, and review/action plan. The educational sessions will be complemented by cancer-specific small media (brochure).
Study: NCT05369676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 1/Ritonavir
Description: Cohort 1:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 2/Ritonavir
Description: Cohort 2:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
Study: NCT05790083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Lotion and Intensive Care
Description: Body Lotion, applied twice daily on whole body, for 3 months. Intensive Care, applied as needed on affected body areas.
Study: NCT04845893

Intervention type: OTHER
Intervention: Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)
Description: This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
Study: NCT05468957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perclose
Description: Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
Study: NCT06142630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alteration of patients' position after erector spinae plane block
Description: After the erector spinae plane block was completed, the patients kept supine, lateral or prone position according to the group allocated for 30 minute to ensure the spread of local anesthetic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alteration of patients' position after erector spinae plane block
Description: After the erector spinae plane block was completed, the patients kept supine, lateral or prone position according to the group allocated for 30 minute to ensure the spread of local anesthetic